HCA Healthcare (HCA) Earnings Dates, Call Summary & Reports

1,791 Followers

Earnings Data

Report Date

Jul 23, 2026

Before Open (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

7.38

Last Year’s EPS

6.84

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 14 Analysts Ratings

Earnings Call Summary

Q1 2026

Earnings Call Date:Apr 24, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call communicated a majority of positive operating and financial developments—revenue growth (+4.3%), strong EPS expansion (~11%), robust cash flow (+22%), sizable share repurchases, and a $200M incremental benefit from Medicaid supplemental programs—while acknowledging several meaningful headwinds including a sharp decline in respiratory-driven volumes, a January winter storm (combined ~$180M EBITDA drag), exchange-related revenue pressure (~$150M Q1; $600M–$900M full-year range), margin compression (‑50 bps) and rising denials. Management characterized the respiratory and weather impacts as temporal, reiterated full-year guidance and reaffirmed resiliency and AI-driven cost-efficiency plans. On balance, the company reported core growth and reinforced confidence in its balance sheet and guidance but faces significant payer and volume dynamics to monitor.

Company Guidance

HCA reaffirmed its 2026 guidance while modeling 2%–3% volume growth for the year and an expected full‑year adjusted‑EBITDA impact from exchange dynamics of $600–$900 million; Q1 revenue was up 4.3% YoY, adjusted EBITDA rose ~2% (margin down 50 bps), adjusted diluted EPS climbed ~11%, cash from operations was $2.0 billion (+22% YoY), capex was $1.1 billion, share repurchases totaled $1.57 billion, dividends were $183 million, and debt/adjusted‑EBITDA sits in the lower half of the target range. Same‑facility Q1 volumes: admissions +0.9% (equivalent +1.3%), inpatient surgeries −0.3%, outpatient surgeries −1.7%, ER visits +0.3%; respiratory admissions were down 42% and respiratory ER visits down 32% (respiratory season + winter storm estimated to reduce Q1 adjusted EBITDA by ~$180M). Medicaid supplemental payments unexpectedly contributed ~+$200M to Q1 adjusted EBITDA (driven by Georgia grandfathering and Texas Atlas reinstatement), prompting an updated full‑year supplemental‑payment assumption of a decline of $50M–$250M vs. prior year; exchange activity cost ~ $150M in Q1, same‑facility exchange equivalent admissions fell ~15% while uninsured equivalent admissions rose ~16%. The company reiterated a $400M resiliency target, reported network expansion of >4% more sites of care, ~1% more hospital beds through capex and ~4% added ER capacity, and noted a $5.5–6.0 billion approved capital project pipeline over the next 24–30 months.

Revenue Growth

Total revenue increased 4.3% year-over-year in Q1 2026.

Adjusted EBITDA and EPS Improvement

Adjusted EBITDA increased almost 2% year-over-year in Q1; diluted earnings per share, as adjusted, increased approximately 11% versus prior-year period.

Strong Operating Cash Flow and Capital Actions

Cash flow from operations was $2.0 billion in the quarter, a 22% increase year-over-year; capital expenditures totaled $1.1 billion; $1.57 billion of shares repurchased and $183 million paid in dividends.

Medicaid Supplemental Payment Benefit

Net benefit from Medicaid supplemental programs increased approximately $200 million to adjusted EBITDA in Q1 (driven by Georgia grandfathered approval, reinstatement of Texas Atlas program and Tennessee benefit).

Network Expansion and Capital Investment

Sites of care expanded by more than 4% vs prior-year quarter, hospital beds increased almost 1% via capital spending, and emergency room capacity increased 4%.

Improved Quality and Operational Metrics

Company reported improved quality measures, increased patient satisfaction and reductions in average length of stay; case mix modestly up with notable growth in cardiac procedures and trauma (trauma +2.5%); patient logistics center admissions +2.4%.

Progress on Digital Transformation and AI

Rollout of AI and digital initiatives expanded (ambient documentation, nurse handoff programs, case management tools) with early productivity and safety improvements cited.

Balance Sheet and Leverage

Debt-to-adjusted EBITDA leverage remains in the lower half of the stated target range and management described the balance sheet as strong and well positioned.

Guidance Reaffirmation and Resiliency Plan

Management reaffirmed full-year 2026 guidance ranges and reiterated expected resiliency savings (approximately $400 million program) and confidence that temporal Q1 headwinds will not change full-year assumptions.

HCA Healthcare (HCA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HCA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 23, 2026	2026 (Q2)	7.38 / -	6.84	―	―	―
Apr 24, 2026	2026 (Q1)	7.12 / 7.15	6.45	10.85% (+0.70)	―
Jan 27, 2026	2025 (Q4)	7.46 / 8.01	6.22	28.78% (+1.79)	―
Oct 24, 2025	2025 (Q3)	5.79 / 6.96	4.9	42.04% (+2.06)	―
Jul 25, 2025	2025 (Q2)	6.29 / 6.84	5.5	24.36% (+1.34)	―
Apr 25, 2025	2025 (Q1)	5.75 / 6.45	5.36	20.34% (+1.09)	―
Jan 24, 2025	2024 (Q4)	6.13 / 6.22	5.9	5.42% (+0.32)	―
Oct 25, 2024	2024 (Q3)	4.96 / 4.90	3.91	25.32% (+0.99)	―
Jul 23, 2024	2024 (Q2)	4.93 / 5.50	4.29	28.21% (+1.21)	―
Apr 26, 2024	2024 (Q1)	5.06 / 5.36	4.93	8.72% (+0.43)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HCA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Apr 24, 2026	$474.03	$432.46	-8.77%
Jan 27, 2026	$471.68	$505.09	+7.08%
Oct 24, 2025	$438.85	$445.71	+1.56%
Jul 25, 2025	$339.86	$332.73	-2.10%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.